NCT03658889 (ARTEMIS) is a clinical trial in Giant Cell Arteritis, sponsored by Chugai Pharma France.

Who is sponsoring NCT03658889?

NCT03658889 is sponsored by Chugai Pharma France.

What condition does NCT03658889 study?

NCT03658889 studies Giant Cell Arteritis.

Is NCT03658889 still recruiting?

NCT03658889 is currently completed. Last updated 22 July 2022.

Are results published for NCT03658889?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2022-07-22 · How we verify

NCT03658889: ARTEMIS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Assessment of Giant Cell Arteritis Medical Practices in France

Completed Results posted Last updated 22 July 2022

What this trial tests

trial in Giant Cell Arteritis in 306 participants. Completed in 9 November 2018.

Timeline

2 August 2018

Primary endpoint
9 November 2018

9 November 2018

Quick facts

Lead sponsor	Chugai Pharma France
Status	Completed
Study type	OBSERVATIONAL
Enrollment	306
Start date	2 August 2018
Primary completion	9 November 2018
Estimated completion	9 November 2018
Sites	1 location across France

Conditions studied

Giant Cell Arteritis — all drugs for Giant Cell Arteritis →

Sponsor

Chugai Pharma France

Who can join

50 and older, any sex, with Giant Cell Arteritis. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Patient Journey : Physicians Who Referred the Patient Primary · Baseline only

Proportion of patients for each physician specialty that referred the patient

General Practitioner

Group	Value	95% CI
Patients Under Treatment(s) for GCA	171

Ophthalmologist

Group	Value	95% CI
Patients Under Treatment(s) for GCA	31

Neurologist

Group	Value	95% CI
Patients Under Treatment(s) for GCA	21

Emergency

Group	Value	95% CI
Patients Under Treatment(s) for GCA	17

Internist

Group	Value	95% CI
Patients Under Treatment(s) for GCA	13

Rheumatologist

Group	Value	95% CI
Patients Under Treatment(s) for GCA	15

Other

Group	Value	95% CI
Patients Under Treatment(s) for GCA	12

Anatomical Pathologist

Group	Value	95% CI
Patients Under Treatment(s) for GCA	0

Patient Journey : Physician Encountered by the Patient at Least One Time Since the First Events Related to GCA Primary · Baseline only

Physician encountered by the patient at least one time since the first events related to GCA (Multiple answers possible, If a patient encountered a medical speciality more than one time, this speciality will be counted only once)

General Practitioner

Group	Value	95% CI
Patients Under Treatment(s) for GCA	260

Ophthalmologist

Group	Value	95% CI
Patients Under Treatment(s) for GCA	88

Neurologist

Group	Value	95% CI
Patients Under Treatment(s) for GCA	38

Emergency

Group	Value	95% CI
Patients Under Treatment(s) for GCA	54

Internist

Group	Value	95% CI
Patients Under Treatment(s) for GCA	59

Rheumatologist

Group	Value	95% CI
Patients Under Treatment(s) for GCA	42

Anatomical pathologist

Group	Value	95% CI
Patients Under Treatment(s) for GCA	3

Angiologist/Vascular surgeon

Group	Value	95% CI
Patients Under Treatment(s) for GCA	17

Patient Journey : Time to GCA Diagnosis Primary · Baseline only

Time between GCA signs/symptoms and diagnosis

Group	Value	95% CI
Patients Under Treatment(s) for GCA	1.00	1.00 – 3.00

GCA Diagnostic Method Primary · Baseline only

Proportions of each diagnostic method used

Erythrocyte Sedimentation Rate (ESR

Group	Value	95% CI
Patients Under Treatment(s) for GCA	154

C-Reactive Protein (CRP)

Group	Value	95% CI
Patients Under Treatment(s) for GCA	266

Biopsy of the Temporal Artery (TAB)

Group	Value	95% CI
Patients Under Treatment(s) for GCA	249

High resolution color Doppler ultrasound

Group	Value	95% CI
Patients Under Treatment(s) for GCA	91

MRI of the temporal arteries

Group	Value	95% CI
Patients Under Treatment(s) for GCA	20

18FDG PET

Group	Value	95% CI
Patients Under Treatment(s) for GCA	74

Aortic angio-CT

Group	Value	95% CI
Patients Under Treatment(s) for GCA	87

GCA Treatments Since Diagnosis : Glucocorticoids Since Diagnosis Primary · Baseline only

GCs treatment since diagnosis : Current GC dose at inclusion and total cumulative GC dose according to investigator (excl. IV bolus) since diagnosis.

Current dose at inclusion

Group	Value	95% CI
Patients Under Treatment(s) for GCA	9.00	5.00 – 20.00

Total cumulative dose

Group	Value	95% CI
Patients Under Treatment(s) for GCA	4305.00	1920.00 – 7000.00

GCA Treatments Since Diagnosis: Glucocorticoids at Inclusion Primary · baseline only

Number of patients with at least one GC kinetic ongoing at inclusion

Group	Value	95% CI
Patients Under Treatment(s) for GCA	273

GCA Treatments Since Diagnosis: Immunosuppressants Stopped Before Inclusion Primary · Baseline only

Immunosuppressants for GCA taken since diagnosis and stopped before inclusion

Azathioprine

Group	Value	95% CI
Patients Under Treatment(s) for GCA	2

Cyclophosphamide

Group	Value	95% CI
Patients Under Treatment(s) for GCA	1

Cyclosporine

Group	Value	95% CI
Patients Under Treatment(s) for GCA	0

Leflunomide

Group	Value	95% CI
Patients Under Treatment(s) for GCA	1

Methotrexate

Group	Value	95% CI
Patients Under Treatment(s) for GCA	25

Mycophenolate Mofetil

Group	Value	95% CI
Patients Under Treatment(s) for GCA	0

Other

Group	Value	95% CI
Patients Under Treatment(s) for GCA	0

GCA Treatments Since Diagnosis: Immunosuppressants Ongoing at Inclusion Primary · Baseline only

Number of patients with at least one immunosuppressant ongoing at inclusion

Azathioprine

Group	Value	95% CI
Patients Under Treatment(s) for GCA	0

Cyclophosphamide

Group	Value	95% CI
Patients Under Treatment(s) for GCA	0

Cyclosporine

Group	Value	95% CI
Patients Under Treatment(s) for GCA	0

Leflunomide

Group	Value	95% CI
Patients Under Treatment(s) for GCA	0

Methotrexate

Group	Value	95% CI
Patients Under Treatment(s) for GCA	35

Mycophenolate Mofetil

Group	Value	95% CI
Patients Under Treatment(s) for GCA	0

Other

Group	Value	95% CI
Patients Under Treatment(s) for GCA	0

GCA Treatments Since Diagnosis: Targeted Biologic Therapies Stopped Before Inclusion Primary · Baseline only

Number of patients who have taken at least one targeted biologic therapy since diagnosis and stopped before inclusion

Adalimumab

Group	Value	95% CI
Patients Under Treatment(s) for GCA	1

Abatacept

Group	Value	95% CI
Patients Under Treatment(s) for GCA	0

Etanercept

Group	Value	95% CI
Patients Under Treatment(s) for GCA	0

Infliximab

Group	Value	95% CI
Patients Under Treatment(s) for GCA	0

Tocilizumab

Group	Value	95% CI
Patients Under Treatment(s) for GCA	9

Other

Group	Value	95% CI
Patients Under Treatment(s) for GCA	0

GCA Treatments Since Diagnosis: Targeted Biologic Therapies Ongoing at Inclusion Primary · Baseline only

Number of patients with at least one targeted biologic therapy ongoing at inclusion

Adalimumab

Group	Value	95% CI
Patients Under Treatment(s) for GCA	0

Abatacept

Group	Value	95% CI
Patients Under Treatment(s) for GCA	0

Etanercept

Group	Value	95% CI
Patients Under Treatment(s) for GCA	0

Infliximab

Group	Value	95% CI
Patients Under Treatment(s) for GCA	1

Tocilizumab

Group	Value	95% CI
Patients Under Treatment(s) for GCA	44

Other

Group	Value	95% CI
Patients Under Treatment(s) for GCA	0

Comorbidities Related to GCs Secondary · Baseline only

Comorbidities related/ aggravated by the use of GCs according to the investigator's judgment in at least 2 patients (by SOC)

Cardiac disorders

Group	Value	95% CI
Patients Under Treatment(s) for GCA	5

Endocrine disorders

Group	Value	95% CI
Patients Under Treatment(s) for GCA	2

Eye disorders

Group	Value	95% CI
Patients Under Treatment(s) for GCA	9

Gastrointestinal disorders

Group	Value	95% CI
Patients Under Treatment(s) for GCA	4

Hepatobiliary disorders

Group	Value	95% CI
Patients Under Treatment(s) for GCA	2

Infections and infestations

Group	Value	95% CI
Patients Under Treatment(s) for GCA	10

Injury, poisoning and procedural complications

Group	Value	95% CI
Patients Under Treatment(s) for GCA	7

Investigations

Group	Value	95% CI
Patients Under Treatment(s) for GCA	4

Treatments in Patients With Comorbidities Related to GCs Secondary · Baseline only

Number of patients with at least one ongoing treatment for comorbidities related to the use of GCs

Group	Value	95% CI
Patients Under Treatment(s) for GCA	98

Sponsor's own description

The purpose of this study is to describe medical practices in patients with GCA in terms of patient journey, diagnostic methods and specific GCA treatments since diagnosis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Presentation and Real-World Management of Giant Cell Arteritis (Artemis Study).
Mahr A, Hachulla E, de Boysson H, Guerroui N, et al · · 2021 · cited 17× · PMID 34859001 · DOI 10.3389/fmed.2021.732934

Verify or expand the search:

Other recruiting trials for Giant Cell Arteritis

Currently open trials in the same condition.

NCT07084480 — Giant Cell Arteritis - Ways to Precision Medicine · recruiting
NCT06894602 — Association of Ultrasonographic Temporal Artery Lesions and Relapse in Patients With Giant Cell Arteritis · recruiting
NCT05935709 — DANIsh VASculitis Database (DANIVAS) · recruiting
NCT06460142 — Assessing Biomarker in Giant Cell Arteritis and Polymyalgia Rheumatic · recruiting
NCT06011512 — Risk of Diabetes Mellitus in Patients With Giant Cell Arthritis and Polymyalgia Rheumatica. · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03658889 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chugai Pharma France
Last refreshed: 22 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03658889.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT03658889: ARTEMIS

Quick facts

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Sponsor's own description

Publications & conference data

Related trials

Other recruiting trials for Giant Cell Arteritis

Verify against primary sources